[
  {
    "ts": "2025-11-14T00:07:43+00:00",
    "headline": "Merck nears deal for flu-prevention biotech Cidara",
    "summary": "Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...",
    "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "feb600a5-727c-382c-96f3-701294a4a06c",
      "content": {
        "id": "feb600a5-727c-382c-96f3-701294a4a06c",
        "contentType": "STORY",
        "title": "Merck nears deal for flu-prevention biotech Cidara",
        "description": "",
        "summary": "Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...",
        "pubDate": "2025-11-14T00:07:43Z",
        "displayTime": "2025-11-14T00:07:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T05:00:00+00:00",
    "headline": "Novo’s New Chairman Urged to Curb Risk After Metsera Drama",
    "summary": "Investors are meeting on Friday to elect Lars Rebien Sorensen to lead the supervisory board less than a week after Novo lost a bidding war with Pfizer Inc. The outcome is a foregone conclusion as the Dane, who ran the company for 16 years, also heads the Novo Nordisk Foundation, the controlling shareholder that holds 77% of Novo’s voting rights.",
    "url": "https://finance.yahoo.com/news/novo-chairman-urged-curb-risk-050000756.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "33199485-1b91-3453-ad37-b168daa959a1",
      "content": {
        "id": "33199485-1b91-3453-ad37-b168daa959a1",
        "contentType": "STORY",
        "title": "Novo’s New Chairman Urged to Curb Risk After Metsera Drama",
        "description": "",
        "summary": "Investors are meeting on Friday to elect Lars Rebien Sorensen to lead the supervisory board less than a week after Novo lost a bidding war with Pfizer Inc. The outcome is a foregone conclusion as the Dane, who ran the company for 16 years, also heads the Novo Nordisk Foundation, the controlling shareholder that holds 77% of Novo’s voting rights.",
        "pubDate": "2025-11-14T05:00:00Z",
        "displayTime": "2025-11-14T05:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/5048dbfd6dc03232007cca42e59d5d74",
          "originalWidth": 1600,
          "originalHeight": 1067,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yyImDYGgGcKqsHHca7ayeQ--~B/aD0xMDY3O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/5048dbfd6dc03232007cca42e59d5d74.cf.webp",
              "width": 1600,
              "height": 1067,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s_i5swtQx0TdQo8H5RNH5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/5048dbfd6dc03232007cca42e59d5d74.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-chairman-urged-curb-risk-050000756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-chairman-urged-curb-risk-050000756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T00:07:43+00:00",
    "headline": "Merck nears $9.2bn deal for flu-prevention biotech Cidara",
    "summary": "Merck is nearing a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu,...",
    "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "feb600a5-727c-382c-96f3-701294a4a06c",
      "content": {
        "id": "feb600a5-727c-382c-96f3-701294a4a06c",
        "contentType": "STORY",
        "title": "Merck nears $9.2bn deal for flu-prevention biotech Cidara",
        "description": "",
        "summary": "Merck is nearing a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu,...",
        "pubDate": "2025-11-14T00:07:43Z",
        "displayTime": "2025-11-14T00:07:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T12:35:47+00:00",
    "headline": "Merck agrees $9.2bn deal for flu-prevention biotech Cidara",
    "summary": "Merck has agreed a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antiviral that protects against flu, after overcoming...",
    "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "feb600a5-727c-382c-96f3-701294a4a06c",
      "content": {
        "id": "feb600a5-727c-382c-96f3-701294a4a06c",
        "contentType": "STORY",
        "title": "Merck agrees $9.2bn deal for flu-prevention biotech Cidara",
        "description": "",
        "summary": "Merck has agreed a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antiviral that protects against flu, after overcoming...",
        "pubDate": "2025-11-14T12:35:47Z",
        "displayTime": "2025-11-14T12:35:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T11:41:52+00:00",
    "headline": "Pfizer Cuts BioNTech Stake by More Than Half",
    "summary": "Move marks shift after years of mRNA collaboration that produced COVID-19 vaccine.",
    "url": "https://finance.yahoo.com/news/pfizer-cuts-biontech-stake-more-114152390.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "3589a91d-cc5a-3200-bac8-a689bc13a9d0",
      "content": {
        "id": "3589a91d-cc5a-3200-bac8-a689bc13a9d0",
        "contentType": "STORY",
        "title": "Pfizer Cuts BioNTech Stake by More Than Half",
        "description": "",
        "summary": "Move marks shift after years of mRNA collaboration that produced COVID-19 vaccine.",
        "pubDate": "2025-11-14T11:41:52Z",
        "displayTime": "2025-11-14T11:41:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vu.kxzmN7yCA.wz8Cs.cHg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Brb0J12XOUXl4lathAg3vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-cuts-biontech-stake-more-114152390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-cuts-biontech-stake-more-114152390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BNTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T12:59:00+00:00",
    "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
    "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
    "url": "https://finance.yahoo.com/news/pharma-etfs-spotlight-following-robust-125900300.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "10fc0cfd-b499-32b5-907f-5817647b3297",
      "content": {
        "id": "10fc0cfd-b499-32b5-907f-5817647b3297",
        "contentType": "STORY",
        "title": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
        "description": "",
        "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
        "pubDate": "2025-11-14T12:59:00Z",
        "displayTime": "2025-11-14T12:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/780f3ed4ed0b380d687c52a84b4582b8",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F9Duz3IXY6vI3GQX0iFRbg--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/780f3ed4ed0b380d687c52a84b4582b8.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jvXjFQvI33DlpnQwQb.s8g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/780f3ed4ed0b380d687c52a84b4582b8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pharma-etfs-spotlight-following-robust-125900300.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharma-etfs-spotlight-following-robust-125900300.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PJP"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "XPH"
            },
            {
              "symbol": "FTXH"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "IHE"
            },
            {
              "symbol": "PPH"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T08:00:00+00:00",
    "headline": "Is that pharma influencer human or AI?",
    "summary": "Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.",
    "url": "https://www.pharmavoice.com/news/ai-pharma-social-media-influencer-drug-eversana/805499/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "81684cb7-59ea-3441-803a-3330b5d1a0c2",
      "content": {
        "id": "81684cb7-59ea-3441-803a-3330b5d1a0c2",
        "contentType": "STORY",
        "title": "Is that pharma influencer human or AI?",
        "description": "",
        "summary": "Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.",
        "pubDate": "2025-11-14T08:00:00Z",
        "displayTime": "2025-11-14T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/387603e9df17fe4993a3a8927227cc90",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Mnpxis3DLYK47xOYN_gwA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/387603e9df17fe4993a3a8927227cc90.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AV2yPZOZExC8AR3Q6SlpaQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/387603e9df17fe4993a3a8927227cc90.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/ai-pharma-social-media-influencer-drug-eversana/805499/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharma-influencer-human-ai-080000016.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T15:53:50+00:00",
    "headline": "Novo Chairman Blames Board Dropout on Former Employer Pfizer",
    "summary": "The executive, who brought Novo’s first weight-loss shot to market, had to spend part of the meeting explaining why proposed board member, Mikael Dolsten, 67, withdrew just a day ago because of an “issue with a former employer.”  “We had very much looked forward to working together with Mikael Dolsten,” Sorensen said.  Pfizer’s acquisition of Metsera closed on Thursday making Novo and its US rival clear competitors in the hottest and fastest-growing pharmaceutical market.",
    "url": "https://finance.yahoo.com/news/novo-chairman-urged-curb-risk-050000756.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "33199485-1b91-3453-ad37-b168daa959a1",
      "content": {
        "id": "33199485-1b91-3453-ad37-b168daa959a1",
        "contentType": "STORY",
        "title": "Novo Chairman Blames Board Dropout on Former Employer Pfizer",
        "description": "",
        "summary": "The executive, who brought Novo’s first weight-loss shot to market, had to spend part of the meeting explaining why proposed board member, Mikael Dolsten, 67, withdrew just a day ago because of an “issue with a former employer.”  “We had very much looked forward to working together with Mikael Dolsten,” Sorensen said.  Pfizer’s acquisition of Metsera closed on Thursday making Novo and its US rival clear competitors in the hottest and fastest-growing pharmaceutical market.",
        "pubDate": "2025-11-14T15:53:50Z",
        "displayTime": "2025-11-14T15:53:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/5048dbfd6dc03232007cca42e59d5d74",
          "originalWidth": 1600,
          "originalHeight": 1067,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yyImDYGgGcKqsHHca7ayeQ--~B/aD0xMDY3O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/5048dbfd6dc03232007cca42e59d5d74.cf.webp",
              "width": 1600,
              "height": 1067,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s_i5swtQx0TdQo8H5RNH5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/5048dbfd6dc03232007cca42e59d5d74.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-chairman-urged-curb-risk-050000756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-chairman-urged-curb-risk-050000756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T11:06:00+00:00",
    "headline": "Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal",
    "summary": "Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.",
    "url": "https://www.biopharmadive.com/news/lundbeck-sparks-bidding-war-with-alkermes-pfizer-closes-metsera-deal/805385/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "f679830c-7873-35a6-b86f-e9fa1f176991",
      "content": {
        "id": "f679830c-7873-35a6-b86f-e9fa1f176991",
        "contentType": "STORY",
        "title": "Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal",
        "description": "",
        "summary": "Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.",
        "pubDate": "2025-11-14T11:06:00Z",
        "displayTime": "2025-11-14T11:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/lundbeck-sparks-bidding-war-with-alkermes-pfizer-closes-metsera-deal/805385/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lundbeck-sparks-bidding-war-alkermes-110600319.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "ALKS"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "KURA"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "ZEAL.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T16:36:02+00:00",
    "headline": "Why Pfizer (PFE) Shares Are Sliding Today",
    "summary": "Shares of global pharmaceutical company Pfizer (NYSE:PFE) fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed other company developments.",
    "url": "https://finance.yahoo.com/news/why-pfizer-pfe-shares-sliding-163602620.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "41a84b72-0aa7-31fa-98d4-f0baf19348d4",
      "content": {
        "id": "41a84b72-0aa7-31fa-98d4-f0baf19348d4",
        "contentType": "STORY",
        "title": "Why Pfizer (PFE) Shares Are Sliding Today",
        "description": "",
        "summary": "Shares of global pharmaceutical company Pfizer (NYSE:PFE) fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed other company developments.",
        "pubDate": "2025-11-14T16:36:02Z",
        "displayTime": "2025-11-14T16:36:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "PFE Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o3tZoPUio75qXATbHoc_Hg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5rZqD7vIoFGnsFYAS_Ztw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-pfizer-pfe-shares-sliding-163602620.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-pfizer-pfe-shares-sliding-163602620.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "BNTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T18:08:48+00:00",
    "headline": "How Recent Moves Are Rewriting the Story for Pfizer",
    "summary": "Pfizer's fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate has climbed slightly as well. Analysts note this shift reflects a blend of enthusiasm for new pipeline additions alongside prudent awareness of industry headwinds. Stay tuned to discover how evolving market developments continue to shape Pfizer's investment outlook and what to watch going forward. Analyst Price Targets don't always capture the full story. Head over to our Company...",
    "url": "https://finance.yahoo.com/news/recent-moves-rewriting-story-pfizer-180848879.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "543fb5e0-b2e5-3b15-8c86-cb747435c666",
      "content": {
        "id": "543fb5e0-b2e5-3b15-8c86-cb747435c666",
        "contentType": "STORY",
        "title": "How Recent Moves Are Rewriting the Story for Pfizer",
        "description": "",
        "summary": "Pfizer's fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate has climbed slightly as well. Analysts note this shift reflects a blend of enthusiasm for new pipeline additions alongside prudent awareness of industry headwinds. Stay tuned to discover how evolving market developments continue to shape Pfizer's investment outlook and what to watch going forward. Analyst Price Targets don't always capture the full story. Head over to our Company...",
        "pubDate": "2025-11-14T18:08:48Z",
        "displayTime": "2025-11-14T18:08:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/recent-moves-rewriting-story-pfizer-180848879.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/recent-moves-rewriting-story-pfizer-180848879.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T17:39:00+00:00",
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Gain insight on bidding wars in the pharmaceuticals sector, Novo Nordisk and more in the latest Market Talks covering the health care sector.",
    "url": "https://www.wsj.com/articles/health-care-roundup-market-talk-87569469?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "545129de-37cc-3ebf-b43e-ddabc6099e38",
      "content": {
        "id": "545129de-37cc-3ebf-b43e-ddabc6099e38",
        "contentType": "STORY",
        "title": "Health Care Roundup: Market Talk",
        "description": "",
        "summary": "Gain insight on bidding wars in the pharmaceuticals sector, Novo Nordisk and more in the latest Market Talks covering the health care sector.",
        "pubDate": "2025-11-14T17:39:00Z",
        "displayTime": "2025-11-14T17:39:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/545129de-37cc-3ebf-b43e-ddabc6099e38/health-care-roundup-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/9b339a1b26fc10e407fdb6cfb57892cb",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.EDPAfFkxyKljp0TPCNgIQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/9b339a1b26fc10e407fdb6cfb57892cb.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Phd3YzVgw6t07q5FuDyLwQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/9b339a1b26fc10e407fdb6cfb57892cb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/articles/health-care-roundup-market-talk-87569469?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "ALKS"
            },
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T16:38:00+00:00",
    "headline": "To Wall Street, a new bidding war puts Alkermes in a tough spot",
    "summary": "Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying significantly more than it had hoped.",
    "url": "https://www.biopharmadive.com/news/avadel-alkermes-lundbeck-bidding-war-acquisition-wall-street-analyst-reaction/805606/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "1b30e8b1-98d6-3105-8b74-b2b71c4407e7",
      "content": {
        "id": "1b30e8b1-98d6-3105-8b74-b2b71c4407e7",
        "contentType": "STORY",
        "title": "To Wall Street, a new bidding war puts Alkermes in a tough spot",
        "description": "",
        "summary": "Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying significantly more than it had hoped.",
        "pubDate": "2025-11-14T16:38:00Z",
        "displayTime": "2025-11-14T16:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/bb3e82fb144acea701a74bd9b3ec4221",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Biotech startups are facing an IPO ‘Groundhog Day’ as the offering slump drags on.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s7W4WflAzMV273ZMMTKgoA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/bb3e82fb144acea701a74bd9b3ec4221.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L5Z4wifzcJmMXRshjLc.Yg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/bb3e82fb144acea701a74bd9b3ec4221.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/avadel-alkermes-lundbeck-bidding-war-acquisition-wall-street-analyst-reaction/805606/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-bidding-war-puts-163800802.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALKS"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "AVDL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T18:02:00+00:00",
    "headline": "Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since",
    "summary": "Eli Lilly's blockbuster drug Zepbound could be getting a big new customer: Medicare. See the implications of the company's recent deal with President Trump.",
    "url": "https://www.marketbeat.com/originals/eli-lilly-strikes-deal-with-trump-why-shares-are-up-10-since/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "2d70a7e1-f8f1-382e-b9c8-ebbedddfb803",
      "content": {
        "id": "2d70a7e1-f8f1-382e-b9c8-ebbedddfb803",
        "contentType": "STORY",
        "title": "Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since",
        "description": "",
        "summary": "Eli Lilly's blockbuster drug Zepbound could be getting a big new customer: Medicare. See the implications of the company's recent deal with President Trump.",
        "pubDate": "2025-11-14T18:02:00Z",
        "displayTime": "2025-11-14T18:02:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/0361fb403376071db39c7d0ce0a749ad",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Lilly logo positioned in front of Lilly's weight loss drug, mounjaro.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rLORU_C.vs4GHJgdUgRXtg--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/0361fb403376071db39c7d0ce0a749ad.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aCEygwThV6s0odqQnKkJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/0361fb403376071db39c7d0ce0a749ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/originals/eli-lilly-strikes-deal-with-trump-why-shares-are-up-10-since/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-strikes-deal-trump-180200113.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]